



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

27 Jul 2020 (#34)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply *ASAP*, but not later than **60 days before the submission date.**

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- [NOT-OD-20-125](#): Reminder FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants
- [Fulbright-Fogarty Fellows in Public Health](#) - Fogarty continues its partnership with the Fulbright Program, the flagship international educational exchange program sponsored by the U.S. government, to promote the expansion of research in public health and clinical research in resource-limited settings for medical and graduate students. Application deadline for 2021-2022: 13 October 2020.
- [Funding opportunities specific to COVID-19](#) from the NIH Office of Extramural Research (OER)

Upcoming Deadlines

- [Global Infectious Disease Research Training](#) D71 28 October 2020
- [HIV Research Training Program for LMIC Institutions](#) 20 August 2020
- [Mobile Health: Technology and Outcomes in LMICs](#) 24 September 2020; AIDS deadline 3 December 2020
- [Fulbright-Fogarty Fellows in Public Health](#) 13 October 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020
- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

- [NOT-AA-20-017](#): Notice of Special Interest: Epidemiology and Prevention in Alcohol Research
- [NOT-AI-20-059](#): Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
- [NOT-CA-20-082](#): Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19).

Funding Opportunities

1. Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Hubs (U54–Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-20-015](#)

Type: U54

Application Due Date: 8 December 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks applications for Research Hubs as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. DS-I Africa Research Hubs will be funded to advance data science health research and innovation in Africa and support new African and global partnerships that enhance the impact of data science health research. Hubs will engage government, industry, or other organizations, including diverse departments from academic institutions, that can partner to provide synergistic expertise, collaborate on research, and support data science linked to new technologies and solutions. Applicants must propose at least 2 distinct research projects and a system for soliciting, evaluating, and awarding smaller pilots projects, all focused on a central health theme that addresses priorities in an African country or region. Applications must be submitted from African academic or other non-profit organizations. Proposed partnerships with organizations outside the applicant institution are required and can include all types of organizations in Africa, the U.S., or other countries.

Budget: The NIH Common Fund intends to commit an estimated total of \$32,500,000 over five years to fund up to 5 awards. The requested budget needs to reflect the actual needs of the proposed project. DS-I Africa Research Hub applications are limited to \$1,300,000 per year in total costs. The scope of the proposed DS-I Africa Research Hub should determine the project period. The maximum project period is 5 years.

2. Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Training Program (U2R Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-20-016](#)

Type: U2R

Application Due Date: 24 November 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks applications for Research Training Programs as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. Through this FOA, DS-I Africa aims to increase capacity to carry out data science health research and innovation in Africa through the support of at least 4 institutional research training cooperative agreement awards. **Applicants should propose long-term data science health research training through graduate degree (master's and/or doctoral) training and faculty development.** Grantees will train cohorts of African investigators who will have the skills to become independent investigators, research leaders, and research collaborators. The cooperative agreements can either be direct awards to African institutions or awards to U.S. institutions in partnership with African institutions. Regardless of the applicant organization, the training programs must focus on building institutional capacity at one or more African institutions and train African researchers. Partnerships with additional organizations, including for-profit or governmental organizations, are encouraged to provide applied research experiences for the trainees. This Funding Opportunity Announcement (FOA) allows appointment of trainees proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: The NIH Common Fund intends to commit an estimated total of \$7,000,000 over five years to fund up to 4 awards. The requested budget needs to reflect the actual needs of the proposed project. Applications are limited \$350,000 total costs per year. The maximum project period is 5 years.

3. Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Ethical, Legal, and Social Implications Research (U01 – Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-20-017](#)

Type: U01

Application Due Date: 1 December 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support research on the Ethical, Legal, and Social Implications (ELSI) associated with a new program entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. A primary goal of this FOA is to explore the ELSI issues impacting

data science for health research from an African perspective and contribute to the policy discussions of such on the continent. Through this FOA and related announcements, it is expected that ELSI research efforts will be fully embedded and integrated components of the consortia of activities supported through related DS-I Africa FOAs. Supported DS-I Africa ELSI awardees will work closely with DS-I Africa coordinating centers and DS-I Africa research hubs in considering how to dynamically address core ethical issues that may arise as the larger research projects uncover additional opportunities in this space. The cooperative agreements made through this FOA must be direct awards to African institutions, but applications can include partnerships with organizations from other areas.

Budget: The NIH Common Fund intends to commit an estimated total of \$8,000,000 over five years to fund up to 4 awards. Application budgets are limited to \$400,000 in total costs in any budget year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Open Data Science Platform and Coordinating Center (U2C – Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-RM-20-018](#)

Type: U2C

Application Due Date: 3 December 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks applications for the development of an Open Data Science Platform and Coordinating Center as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. The FOA is comprised of two components – the DS-I Africa Open Data Science Platform (ODSP) and Coordinating Center (CC) – funded via one U2C award. The ODSP core will develop and maintain a scalable data-sharing gateway available to the research community with access to disparate types of open and controlled-access data and tools, generated from the DS-I Africa Research Hubs as well as other existing sources. The CC core will provide the organizational framework for the management, direction, and overall coordination of all common DS-I Africa consortium activities. The cooperative agreement will be awarded to an African academic or other non-profit institution. Multisectoral partnerships with other organizations in Africa, the U.S., or other countries are encouraged.

Budget: The NIH Common Fund intends to commit an estimated total of \$11,250,000 over five years to fund 1 award. \$2,250,000 total costs per year. The maximum project period is 5 years

5. Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-269](#)

Type: R01

Application Due Date: Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions.

Budget: NIA intends to commit \$5.5 million in FY 2021 to support 2-5 awards. Annual direct costs are capped at \$750,000. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-045](#)

Type: R01

Application Due Date: December 16, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This limited competition Funding Opportunity Announcement (FOA) solicits the renewal application for the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Hazards to Humans. The IARC Monographs program, which is supported in part by the NCI, critically evaluates the published scientific evidence on carcinogenic hazards to humans. Monograph volumes are considered critical references that inform health policy and cancer research worldwide about carcinogenic hazards to reduce cancer burden globally.

Budget: The NCI intends to commit \$900,878 in FY 2021 to fund one award. The application budget is limited to \$793,135 in direct costs per year and should reflect the actual needs of the project. The applicant may request a project period of 5 years.

7. Tobacco Use and HIV in Low and Middle-Income Countries (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-037](#)

Type: U01

Application Due Date: 24 September 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the development and evaluation of tobacco cessation interventions tailored to HIV-positive populations, including those with comorbidities such as tuberculosis (TB), in low-resource settings in low- and middle-income countries (LMICs). In particular, this FOA aims to bring together transdisciplinary teams of investigators to adapt interventions developed and tested in other challenging settings or low-resource populations and to test their robustness among persons living with HIV (PLWH) in LMICs. Responsive applications must propose research that will be conducted with PLWH in one or more LMICs and will inform efforts to reduce tobacco-related morbidity and mortality among PLWH. Research may also address the behavioral and sociocultural factors and conditions that are associated with tobacco use among PLWH and may also address tobacco-related health disparities among PLWH.

Budget: Application budgets are limited to \$500,000 in direct costs in any one year. The maximum project period is 5 years.

8. Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-21-004](#)

Type: UG3/UH3

Application Due Date: 14 October 2020, by 11:59 PM Eastern Time.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.

The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase. UH3 phase awards will be awarded after administrative review of eligible UG3 phase awards that have met the scientific milestone and feasibility requirements necessary for UH3 phase implementation. The number of awards is dependent on the availability of funds. The UG3/UH3 application must be submitted as a single application, and applicants should note specific instructions for each phase in this FOA. The total award project period will not exceed 5 years.

Budget: FDA/CDER intends to commit up to \$4,200,000 total for fiscal year 2021 to fund up to three (3) awards in support of this grant program. The scope of the proposed project should determine the project period. The UG3 phase is limited to up to two years and the UH3 phase can request up to four years of support. The total project period for an application submitted in response to this FOA may not exceed five (5) years.

UG3 (up to 2 years): Combined years: up to \$1,400,000 total costs/per award. It is up to the applicant to determine the number of years and budget for the UG3 phase. The application should provide justification for the number of years and budget split among the years if the UG3 phase is anticipated to take more than 1 year. **UH3 (up to 4 years):** Combined years: up to \$2,700,000 total costs/award. It is up to the applicant to determine the number years and budget for the UH3 phase. The application should provide justification for the number of years for the UH3 phase and budget split among the years.

9. Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-271](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 4 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/Research Contact at least 6 weeks before submitting the application

10. Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-276](#)
[PAR-20-277](#)

Type: R01
R21

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.

Budget: R01 = The budget is limited to \$350,000 direct costs per year and should reflect the actual needs of the proposed project. The maximum project period is 5 years. R21 = Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is 2 years.

11. Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-281](#)
[PAR-20-282](#)

Type: R01
R21

Application Due Date: 19 October 2020, 19 June 2021, 19 February 2022, 19 October 2022, 19 June 2023 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. Advancing this premise will require substantive involvement of experts in reproductive health/fertility along with expert in another non-reproductive specialty appropriate to the area of overall health being investigated, for example, in other fields such as epidemiology, or the somatic disease in

question. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of the disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA.

Budget: R01 = Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. R21 = The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

12. Chronic Kidney Diseases of Uncertain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Field Epidemiology Sites (U01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-20-017](#)

Type: U01

Application Due Date: 10 November 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications for Field Epidemiology Sites (FES) to enroll research participants in the consortium to study Chronic Kidney Disease of Uncertain Etiology (CKDu) in Agricultural Communities (CURE). The FES will recruit, enroll and follow participants with evidence of CKDu and appropriate control participants; collect data and conduct clinical assessments; collect biological and environmental samples; and maintain partnerships with local leaders, health care providers, health ministries, or governments. This collaborative research consortium will bring together a broad range of expertise and enable discovery science to understand the cause or causes of CKDu and disease progression. The Consortium will also work to identify potential therapeutic targets and public health interventions. The Consortium will consist of a Scientific Data Coordinating Center (SDCC), Field Epidemiology Sites (FES), a Renal Science Core (RSC), and the Human Health Exposure Analysis Resource (HHEAR). The Consortium will work together to finalize ethical epidemiology research designs, execute common strategies for biological sampling and environmental assessment, apply the best analytic strategies for collected samples and data, and disseminate results to the global research and public health communities. The final design of the study, as determined by the Steering Committee, may significantly vary from individual applications. It is required that all funded sites fully abide with the final harmonized design set by the Consortium Steering Committee.

This FOA will not support clinical trial or intervention trials. This FOA is intended to support only human studies; applications that include animal or model systems are not responsive.

Budget: NIDDK, NIEHS and FIC intend to commit up to \$4,000,000 in Fiscal Year 2021 to support the three related funding opportunities RFA-DK-20-017, RFA-DK-20-018, and RFA-DK-20-019 and anticipate awarding 1 Scientific Data Coordinating Center, 1 Renal Science Core and 3-4 Field Epidemiology Sites. The direct costs for this award are anticipated to be no more than \$400,000 in direct costs for each award in Year 1 and Year 2. Application budgets are anticipated to be no more than \$300,000 in direct costs in Years 3-5. Application budgets need to reflect the actual needs of the proposed project. Award budgets will vary each year depending upon the scientific needs and opportunities of the Consortium. The maximum project period is 5 years.

13. Chronic Kidney Diseases of Uncertain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium – Renal Science Core (U01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DK-20-018](#)

Type: U01

Application Due Date: 10 November 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications for a Renal Science Core (RSC) to support and provide scientific guidance as part of a new consortium to study Chronic Kidney Disease of Uncertain Etiology (CKDu) in Agricultural Communities (CURE). The RSC will provide scientific expertise in planning clinical phenotyping and measures of renal function; will guide strategies for biological sampling and handling; and will provide needed clinical laboratory based measures and renal pathology. The RSC will also provide renal pathophysiologic expertise to propose approaches, novel measures (e.g., omics and molecular markers) and interpret discovery science to elucidate the cause or causes of CKDu. This collaborative research consortium will bring together a broad range of expertise and enable discovery science to understand the cause or causes of CKDu and disease progression. The Consortium will also work to identify potential therapeutic targets and public health interventions. The Consortium will consist of a Scientific Data Coordinating Center (SDCC), Field Epidemiology Sites (FES), a Renal Science Core (RSC), and the Human Health Exposure Analysis Resource (HHEAR). The Consortium will work together to finalize ethical epidemiology research designs, execute common strategies for biological sampling and environmental assessment, apply the best analytic strategies for collected samples and data, and disseminate results to the global research and public health communities. The final design of the study, as determined by the Steering Committee, may significantly vary from individual applications. It is required that all funded sites fully abide with the final harmonized design set by the Consortium Steering Committee. This FOA will not support clinical trial or intervention trials. This FOA is intended to support only human studies; applications that include animal or model systems are not responsive.

Budget: NIDDK and NIEHS intend to commit \$4,000,000 in Fiscal Year 2021 to support the three related funding opportunities RFA-DK-20-017, RFA-DK-20-018, and RFA-DK-20-019. We anticipate awarding 1 Scientific Data Coordinating Center, 1 Renal Science Core and 3-4 Field Epidemiology Sites. Application budgets need to reflect the actual needs of the proposed project. Application budgets are anticipated to be no more than \$400,000 direct costs per year for Years 1 and 2 and no more than \$500,000 in Years 3-5. Award budgets will vary from year to year depending upon the scientific needs and opportunities of the consortium. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105